b
r
c
hcmv
infect
repres
lifethreaten
condit
immunocompromis
patient
newborn
infant
novel
antihcmv
agent
clearli
need
regard
seri
x
phenoxi
alkyl
uracil
deriv
synthes
examin
antivir
properti
compound
found
exhibit
highli
specif
promis
inhibitori
activ
hcmv
replic
hel
cell
cultur
ec
valu
within
lm
rang
studi
undertaken
elucid
mechan
action
compound
structureact
relationship
linker
region
human
cytomegaloviru
hcmv
belong
viral
famili
known
herpesvirida
also
known
human
within
herpesvirida
hcmv
belong
betaherpesvirina
subfamili
one
characterist
featur
herpesvirus
includ
hcmv
abil
remain
latent
within
bodi
infect
latent
hcmv
present
approxim
adult
age
us
typic
goe
unnot
healthi
peopl
lifethreaten
immunocompromis
person
regard
hivinfect
person
organ
transplant
recipi
newborn
infant
high
risk
infect
transplacent
hcmv
transmiss
lead
congenit
abnorm
stillbirth
thu
repres
one
common
viral
caus
birth
defect
hcmv
infect
may
also
caus
mucoepidermoid
carcinoma
possibl
malign
moreov
number
studi
reveal
hcmv
associ
autoimmun
diseas
atherosclerosi
coronari
restenosi
increas
risk
diabet
date
three
antihcmv
agent
ganciclovir
cidofovir
foscarnet
approv
clinic
use
exhibit
effect
inhibit
activ
hcmv
polymeras
thu
reduc
viral
replic
patient
recogn
hcmv
infect
symptom
use
drug
howev
sever
limit
toxic
addit
due
inher
poor
oral
bioavail
must
administ
intraven
reach
appropri
therapeut
level
except
limit
valganciclovir
oral
administ
prodrug
ganciclovir
unfortun
typic
mani
nucleosid
drug
develop
drugresist
viral
strain
emerg
thu
urgent
need
new
effect
antihcmv
agent
improv
activ
pharmacokinet
profil
recent
new
class
nonnucleosid
hcmv
polymeras
inhibitor
attract
interest
result
biochem
pharm
screen
campaign
seri
hcmv
inhibitor
identifi
highest
activ
exhibit
compound
fig
possess
orthosubstitut
benzyl
moieti
subsequ
design
modif
led
macrocycl
analogu
repres
compound
exhibit
potent
activ
hcmv
herpesvirus
howev
accompani
signific
cytotox
potent
antihcmv
antivzv
activ
also
note
heterocyclicbas
inhibitor
includ
imidazo
pyridin
deriv
benzothiadiazin
exampl
broadspectrum
herpesviru
inhibitor
repres
deriv
fuse
heterocycl
system
includ
quinolon
develop
pfizer
fig
note
compound
possess
common
structur
featur
nheterocycl
link
benzen
ring
previous
report
synthesi
antivir
properti
number
differ
class
nucleobas
deriv
specif
antihiv
antihcmv
activ
seri
phenoxi
ethyl
benzyloxi
ethyl
deriv
adenin
describ
phenoxi
ethoxi
methyl
uracil
found
moder
activ
hiv
ethyl
deriv
exhibit
strong
inhibitori
properti
addit
sever
deriv
cinnamyl
uracil
demonstr
signific
activ
hiv
hcmv
replic
cell
cultur
result
observ
provid
strong
impetu
explor
antivir
activ
spectrum
x
phenoxi
alkyl
uracil
well
investig
structur
requir
linker
aromat
moieti
sinc
scaffold
common
mani
known
inhibitor
hcmv
polymeras
seri
novel
uracil
deriv
synthes
similar
manner
previous
describ
group
condens
equimolar
amount
trimethylsilyl
pyrimidin
bromid
perform
absenc
solvent
afford
target
compound
yield
scheme
compound
obtain
yield
alkalin
hydrolysi
reflux
waterethanol
h
scheme
reduct
compound
accomplish
sncl
mild
acidfre
condit
produc
aminosubstitut
compound
yield
antihcmv
properti
target
compound
evalu
hcmv
davi
strain
hel
cell
cultur
result
shown
tabl
compound
prove
inhibitori
hcmv
examin
structur
activ
relationship
compound
appear
activ
strongli
depend
upon
substitu
paraposit
benzen
core
polar
group
prove
unfavor
result
loss
activ
compound
activ
alkyl
substitut
compound
increas
size
substitu
ec
h
ipr
tbu
howev
introduct
bulki
phenyl
group
led
poor
activ
thu
appear
steric
limit
substitut
compound
found
exhibit
highest
activ
compar
ganciclovir
interestingli
compound
essenti
inact
one
possibl
rational
observ
could
complementari
polar
interact
halogenor
cyanosubstitu
appropri
protein
function
exampl
carbonyl
group
sinc
oxygencontain
compound
inact
assumpt
partial
support
fact
reduct
group
inact
compound
led
substitut
compound
exhibit
slight
antihcmv
activ
substitut
posit
five
uracil
ring
also
examin
regard
thymin
analogu
slightli
activ
uracil
deriv
halogensubstitut
activ
notabl
diminish
result
modif
investig
initi
select
investig
optim
length
linker
chain
uracil
benzen
moieti
compound
contain
three
four
six
methylen
respect
found
inact
hcmv
subtox
concentr
contrast
compound
eight
methylen
unit
demonstr
level
activ
seri
novel
x
phenoxi
alkyl
uracil
deriv
synthes
shown
promis
highli
specif
inhibitori
properti
hcmv
replic
cell
cultur
notabl
substitut
pattern
benzen
core
appear
import
activ
ec
valu
activ
compound
seri
compound
lie
within
rang
lm
accompani
low
cytotox
cc
p
lm
addit
effort
current
underway
elucid
mechan
action
compound
explor
structureact
relationship
linker
region
reagent
obtain
highest
grade
avail
sigma
acro
organ
use
without
purif
unless
otherwis
note
anhydr
dmf
isopropanol
purchas
sigmaaldrich
co
anhydr
aceton
ethyl
acet
obtain
distil
p
nmr
spectra
regist
bruker
avanc
spectromet
mhz
h
mhz
c
dmsod
tetramethylsilan
intern
standard
data
report
follow
order
multipl
br
broad
singlet
doublet
dd
doublet
doublet
triplet
multiplet
q
quartet
qu
quintet
tlc
perform
merck
tlc
silica
gel
f
plate
elut
ethyl
acet
chloroformmeoh
develop
uvlamp
franc
acro
organ
belgium
silica
gel
kieselgur
lm
use
column
chromatographi
melt
point
determin
glass
capillari
meltemp
laboratori
devic
inc
us
yield
refer
spectroscop
h
c
nmr
homogen
materi
high
resolut
mass
spectra
measur
bruker
microtof
ii
instrument
use
electrospray
ioniz
hresim
measur
done
posit
ion
mode
interfac
capillari
voltag
v
mass
rang
mz
da
extern
intern
calibr
done
esi
tune
agil
technolog
syring
inject
use
solut
acetonitril
flow
rate
llmin
nitrogen
appli
dri
ga
interfac
temperatur
set
bromid
synthes
per
known
procedur
compound
evalu
follow
virus
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
lyon
g
human
cytomegaloviru
hcmv
strain
davi
varicellazost
viru
strain
oka
ys
vaccinia
viru
lederl
strain
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
parainfluenza
influenza
viru
subtyp
influenza
viru
b
sindbi
punta
toro
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
african
green
monkey
cell
vero
human
epitheli
cell
hela
madindarbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
hcmv
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
inhibit
iii
b
rod
induc
cytopath
cem
cell
cultur
measur
microtit
plate
contain
cem
cellsml
infect
ccid
hiv
per
millilit
contain
appropri
dilut
test
compound
day
incub
co
control
humidifi
atmospher
cem
giant
syncytium
cell
format
examin
microscop
ec
effect
concentr
defin
compound
concentr
requir
inhibit
hivinduc
giant
cell
format
assay
perform
microtit
plate
well
ad
tumor
cell
given
amount
test
compound
cell
allow
prolifer
h
murin
leukemia
cell
h
human
lymphocyt
cem
human
cervix
carcinoma
hela
cell
humidifi
co
control
atmospher
end
incub
period
cell
count
coulter
counter
ic
inhibitori
concentr
defin
concentr
compound
inhibit
cell
prolifer
